WO2025190364 - KIF18A INHIBITOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/190364
Publication Date
18.09.2025
International Application No.
PCT/CN2025/082448
International Filing Date
13.03.2025
Title **
[English]
KIF18A INHIBITOR AND USE THEREOF
[French]
INHIBITEUR DE KIF18A ET SON UTILISATION
[Chinese]
KIF18A抑制剂及其用途
Applicants **
SHANDONG XUANZHU PHARMA CO., LTD.
Inventors
LIU, Bin
CHEN, Bo
Priority Data
202410294280.5
14.03.2024
CN
202410405681.3
03.04.2024
CN
202410543716.X
30.04.2024
CN
202411964753.4
30.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2091 | |
| EPO | Filing, Examination, Granting | 12556 | |
| Japan | Filing, Examination, Granting | 2138 | |
| South Korea | Filing, Examination, Granting | 2148 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,673
Contact Us
Abstract[English]
The present invention relates to the technical field of medicine; and specifically relates to a KIF18A inhibitor compound or a pharmaceutically acceptable salt, an ester, a deuterated substance or a stereoisomer thereof, a pharmaceutical composition and a formulation containing the compound or the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer thereof, a method for preparing the compound or the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer thereof, and the use of the compound or the pharmaceutically acceptable salt, the ester, the deuterated substance or the stereoisomer thereof in the preparation of a drug for treating and/or preventing diseases mediated by KIF18A and related diseases.[French]
La présente invention se rapporte au domaine technique de la médecine ; et concerne plus précisément un composé inhibiteur de KIF18A ou un sel pharmaceutiquement acceptable, un ester, une substance deutérée ou un stéréoisomère de celui-ci, une composition pharmaceutique et une formulation contenant le composé ou le sel pharmaceutiquement acceptable, l'ester, la substance deutérée ou le stéréoisomère de celui-ci, un procédé de préparation du composé ou du sel pharmaceutiquement acceptable, de l'ester, de la substance deutérée ou du stéréoisomère de celui-ci, et l'utilisation du composé ou du sel pharmaceutiquement acceptable, de l'ester, de la substance deutérée ou du stéréoisomère de celui-ci dans la préparation d'un médicament pour le traitement et/ou la prévention de maladies médiées par KIF18A et de maladies associées.[Chinese]
本发明涉及医药技术领域，具体涉及KIF18A抑制剂化合物、其药学上可接受的盐、其酯、氘代物或其立体异构体，含有所述化合物、其药学上可接受的盐、其酯、氘代物或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其酯、氘代物或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其酯、氘代物或其立体异构体在制备治疗和/或预防由KIF18A介导的疾病及相关疾病的药物中的用途。